Nuvation Bio Inc. (NUVB) Price Target Lowered as IBTROZI Sales Meet Expectations

TheFly reported connected January 12 that H.C. Wainwright reduced its terms people connected NUVB to $17 from $18 portion maintaining a Buy rating. The steadfast said the company’s fourth-quarter Ibtrozi income came successful enactment with expectations.

On the aforesaid day, NUVB reported preliminary Q4 2025 nett merchandise gross of astir $15.7 cardinal for IBTROZI (taletrectinib). The institution besides highlighted that 216 caller patients started attraction with IBTROZI successful the 4th fourth and received a $25 cardinal milestone outgo from Nippon Kayaku.

Nuvation Bio Inc. (NYSE:NUVB) is simply a clinical-stage biopharmaceutical institution focused connected processing innovative therapies for oncology patients. Its pb asset, IBTROZI (taletrectinib), targets uncommon and difficult-to-treat cancers. The institution emphasizes precision medicine, pipeline expansion, and improving outcomes for patients with constricted therapeutic options successful oncology.

While we admit the imaginable of NUVB arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.